Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic

Paoli, Marine De; Perco, Paul; Mühlberger, Irmgard; Lukas, Arno; Pandha, Hardev; Morgan, Richard; Feng, Gui Jie; Marquette, Christophe A.

doi:10.3109/1354750x.2015.1068867

Cited by 9 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A considerable increase in the AUC score for 6 combinations: CerP(23:1)/SM(40:1); S1P(20:2)/SM(18:2/22:0); S1P(20:2)/SM(40:1); S1P(22:2)/SM(18:2/22:0); S1P(22:2)/SM(40:1); SM(18:0/24:2)/SM(18:2/22:0)/SM(40:1) was observed suggesting that these sphingolipid metabolite sets can be used efficiently to distinguish tumor tissues from adjacent normal breast tissues. Cumulative ROC analysis has also been used to improve the biomarkers performance in other cancer types 55,56 .…”

Section: Discussionmentioning

confidence: 99%

LC-HRMS based approach to identify novel sphingolipid biomarkers in breast cancer patients

Bhadwal¹,

Dahiya²,

Shinde³

et al. 2020

Sci Rep

View full text Add to dashboard Cite

perturbations in lipid metabolic pathways to meet the bioenergetic and biosynthetic requirements is a principal characteristic of cancer cells. Sphingolipids (SpLs) are the largest class of bioactive lipids associated to various aspects of tumorigenesis and have been extensively studied in cancer cell lines and experimental models. the clinical relevance of SpLs in human malignancies however is still poorly understood and needs further investigation. in the present study, we adopted a UHpLc-High resolution (orbitrap) Mass spectrometry (HRMS) approach to identify various sphingolipid species in breast cancer patients. A total of 49 SPLs falling into 6 subcategories have been identified. Further, integrating the multivariate analysis with metabolomics enabled us to identify an elevation in the levels of ceramide phosphates and sphingosine phosphates in tumor tissues as compared to adjacent normal tissues. the expression of genes involved in the synthesis of reported metabolites was also determined in local as well as TCGA cohort. A significant upregulation in the expression of CERK and SPHK1 was observed in tumor tissues in local and tcGA cohort. Sphingomyelin levels were found to be high in adjacent normal tissues. Consistent with the above findings, expression of SGMS1 in tumor tissues was downregulated in tcGA cohort only. clinical correlations of the selected metabolites and their performance as biomarkers was also evaluated. Significant ROC and positive correlation with Ki67 index highlight the diagnostic potential and clinical relevance of ceramide phosphates in breast cancer.Dysregulation of lipid homeostasis has become an established hallmark of cancer. The cancer cells exploit lipid metabolic pathways in order to fulfil their demand for energy as well as biosynthetic precursors. Aberrations in lipid metabolism thus affects numerous cellular processes such as cell growth, proliferation, differentiation and cell survival 1 . Sphingolipids (SPLs), apart from the inceptive view of being considered as mere structural components, have evolved as crucial regulators of myriads of cellular functions. The primary elements of sphingolipid metabolism such as ceramide, ceramide 1-phosphate and sphingosine 1-phosphate have recently emerged as key regulators in cancer cell growth, proliferation, survival, migration and drug resistance 2-4 . Numerous studies have described the elementary role of ceramide and sphingosine 1-phosphate rheostat in various types of cancers such as lung, breast and colon. However, these studies have provided the mechanistic details of sphingolipid metabolism in cancer cell lines and experimental models 5-7 , while their role in human malignancies is still poorly understood and needs further elucidation.Breast cancer continues to remain the most common malignancy among women worldwide 8 . The diagnosis rate of breast cancer among Indian females is as high as 25.8 per 100,000 women with a mortality rate of 12.7 per 100,000 women 9 . Despite advancement in diagnostic and therapeutic modalities, th...

show abstract

Section: Discussionmentioning

confidence: 99%

LC-HRMS based approach to identify novel sphingolipid biomarkers in breast cancer patients

Bhadwal¹,

Dahiya²,

Shinde³

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…We have measured levels of urinary and plasma VEGF-A in the same study population. While VEGF-A was already described as a component of variety of multi-marker diagnostic tests and its prognostic value in bladder cancer patients was reported, no study evaluating PLGF as a diagnostic or prognostic marker of bladder cancer has been published to date (18)(19)(20)(21).…”

Section: Discussionmentioning

confidence: 99%

Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A

Soukup

Čapoun

Pešl

et al. 2018

View full text Add to dashboard Cite

“…Several papers reported that HER2 positivity may predict muscle invasion in urothelial cancer of the urinary bladder (33,34,35). Based on previous studies regarding HER2 involvement in tumor progression from bladder cancer, this oncoprotein was included in newly designed multiplatform biomarkers designed to be used in clinical practice to predict invasion and reccurence in patients with urothelial cancer (36,37,38). Our data support the HER2 role in the local invasion of urothelial tumors, most of the cases scored as +2 and +3 being staged into T3 (a or b) group.…”

Section: Discussionmentioning

confidence: 99%

Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach?

Cîmpean

Tarlui

Cumpanas

et al. 2017

View full text Add to dashboard Cite

show abstract

Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic

Cited by 9 publications

References 25 publications

LC-HRMS based approach to identify novel sphingolipid biomarkers in breast cancer patients

LC-HRMS based approach to identify novel sphingolipid biomarkers in breast cancer patients

Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A

Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach?

Contact Info

Product

Resources

About